# US 2024/0189359 A1 · Combination therapy comprising a composition of mesenchymal stromal cells and hyaluronic acid for use in treatment of osteoarthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189359 A1
- Document ID: US20240189359A1
- Status: Published application
- Kind: A1
- Application number: 18/147,269
- Filed: 2022-12-28
- Published: 2024-06-13
- Earliest claimed: 2022-12-07
- Assignees: Stempeutics Research Private Limited
- Applicants: Stempeutics Research Private Limited
- Inventors: Pawan Kumar GUPTA; Udaykumar KOLKUNDKAR; Shivashankar PARASHURAM; Suresh Kannan Subramanian SHANMUGAM
- Web page: https://patentgrep.com/patent/US20240189359A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/728: Hyaluronic acid
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to an ultrasound guided intraarticular administration of a combination of a composition comprising pooled mesenchymal stromal cells, and mid molecular weight hyaluronic acid for treatment of osteoarthritis. The disclosure also provides methods for increasing levels of anti-inflammatory marker and decreasing levels of disease progression marker in a human subject suffering from osteoarthritis through the use of the said combination. The present disclosure accordingly also relates to a kit comprising the said composition and the hyaluronic acid as such for the said use and treatment.

## Claims

### Claim 1

A method of treating osteoarthritis in a human subject, said method comprising administering to the subject a combination of:
a composition comprising about 20 to 30 million mesenchymal stromal cells, about 1 ml of multiple electrolyte solution and about 1 ml of protein free, serum free, animal component free formulation of about 2.5% to 5% dimethyl sulfoxide (DMSO); and
about 2 ml of mid molecular weight hyaluronic acid,
wherein the composition is devoid of human serum albumin (HSA);
wherein the mesenchymal stromal cells are bone marrow derived pooled mesenchymal stromal cells obtained from pooling mesenchymal stromal cells from at least 3 donors; and
wherein the administration of the composition or the hyaluronic acid or both, is an ultrasound guided administration, through an intra-articular route.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the osteoarthritis is a Grade II or Grade III osteoarthritis.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the multiple electrolyte solution is Plasmalyte A.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein each of the composition and hyaluronic acid are administered through a single intra-articular administration.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein at least one or both of the composition and hyaluronic acid are administered through an ultrasound guided intra-articular administration.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the composition and hyaluronic acid are administered simultaneously or sequentially.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein the hyaluronic acid is administered post 1 second to 30 minutes of the administration of the composition.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein the combination provides improvement to the subject in osteoarthritic symptoms selected from a group comprising pain, stiffness and compromised physical function; and improves or maintains quality of cartilage in the subject, in relation to the subject prior to the administration of the said combination.

### Claim 9 (depends on 8)

The method as claimed in claim 8, wherein the combination improves mean percentage change from baseline or placebo in at least one of WOMAC composite index score or WOMAC pain index score or WOMAC stiffness index score or WOMAC physical function index score or VAS score by at least about 10% in a span of about 6 months.

### Claim 10 (depends on 8)

The method as claimed in claim 8, wherein the combination shows a mean difference in percentage change from baseline or placebo for at least one of WOMAC composite index score or WOMAC pain index score or WOMAC stiffness index score or WOMAC physical function index score or VAS score by at least about 15% at the 6 months timepoint.

### Claim 11 (depends on 8)

The method as claimed in claim 8, wherein the combination shows a mean difference in percentage change from baseline or placebo for at least one of WOMAC composite index score or WOMAC pain index score or WOMAC stiffness index score or WOMAC physical function index score or VAS score by at least about 20% at the 12 months timepoint.

### Claim 12 (depends on 1)

The method as claimed in claim 1, wherein the combination increases levels of plasma anti-inflammatory marker interleukin-10 (IL-10) and decreases levels of disease progression urinary marker crosslinked C-telopeptides of type II collagen (CTX-II) in the subject, in relation to the subject prior to the administration of the said combination.

### Claim 13 (depends on 1)

The method as claimed in claim 1, wherein the composition comprises 25 million mesenchymal stromal cells.

### Claim 14

A combination product or a kit for treating osteoarthritis in a human subject, comprising a combination of:
a composition comprising about 20 to 30 million mesenchymal stromal cells, about 1 ml of multiple electrolyte solution and about 1 ml of protein free, serum free, animal component free formulation of about 2.5% to 5% dimethyl sulfoxide (DMSO); and
about 2 ml of mid molecular weight hyaluronic acid,
wherein the composition is devoid of human serum albumin (HSA); and
wherein the mesenchymal stromal cells are bone marrow derived pooled mesenchymal stromal cells obtained from pooling mesenchymal stromal cells from at least 3 donors.

### Claim 15

A method of increasing levels of plasma anti-inflammatory marker interleukin-10 (IL-10) and/or decreasing levels of disease progression urinary marker crosslinked C-telopeptides of type II collagen (CTX-II) in a human subject suffering from osteoarthritis, said method comprising administering to the subject a combination of:
a. a composition comprising about 20 to 30 million mesenchymal stromal cells, multiple electrolyte solution and protein free, serum free, animal component free formulation of dimethyl sulfoxide (DMSO); and
b. mid molecular weight hyaluronic acid,
wherein the composition is devoid of human serum albumin (HSA);
wherein the mesenchymal stromal cells are bone marrow derived pooled mesenchymal stromal cells obtained from pooling mesenchymal stromal cells from at least 3 donors; and
wherein when the combination is administered to the subject, the levels are increased and/or decreased in relation to the subject prior to administration of the said combination.

### Claim 16 (depends on 15)

The method as claimed in claim 15, wherein the administration of the composition or the hyaluronic acid or both, is an ultrasound guided administration, through an intra-articular route.
